Both Tests Are Essential—Order Them Together
For patients on antipsychotic medications, you need BOTH fasting glucose and a lipid panel, not one or the other. The most recent international guidelines explicitly require both tests as part of comprehensive metabolic monitoring 1.
Why Both Tests Are Required
Antipsychotic medications—particularly second-generation agents like olanzapine, clozapine, and quetiapine—cause distinct metabolic derangements that affect both glucose metabolism and lipid profiles independently 2. These are separate pathophysiological processes that require separate monitoring:
- Glucose dysregulation: Antipsychotics increase diabetes risk through multiple mechanisms including weight gain, insulin resistance, and direct effects on glucose metabolism
- Dyslipidemia: These medications independently elevate triglycerides, LDL cholesterol, and total cholesterol, increasing cardiovascular risk
Specific Monitoring Protocol
At Baseline (Before Starting Antipsychotics)
Order the following 1:
- Fasting glucose (or HbA1c)
- Complete lipid panel (total cholesterol, LDL, HDL, triglycerides)
- BMI and waist circumference
- Blood pressure
Early Follow-up
- Recheck fasting glucose at 4 weeks after initiation 1
- If fasting sample cannot be obtained, use random glucose as initial screen, then prioritize fasting if abnormal 1
Ongoing Monitoring
- Repeat both glucose and lipids at 3 months, then annually thereafter 1
- More frequent monitoring (quarterly) may be warranted for high-risk agents like olanzapine and clozapine 3
Practical Considerations
The fasting requirement is a common barrier. While fasting samples are preferred for both tests, recent evidence shows:
- Non-fasting lipid panels are acceptable alternatives and show minimal variation from fasting values (except triglycerides, which vary ~20%) 4
- Random glucose can serve as initial screening, with fasting glucose obtained if abnormal 1
Don't let perfect be the enemy of good—if a patient cannot fast, obtain non-fasting samples rather than skipping monitoring entirely.
High-Risk Medications Requiring Vigilant Monitoring
The 2024 ADA guidelines specifically identify second-generation antipsychotics as requiring "greater monitoring" 2. Risk stratification by agent:
Higher metabolic risk (monitor more closely):
- Olanzapine
- Clozapine
- Quetiapine
- Risperidone
Lower metabolic risk:
- Aripiprazole
- Ziprasidone
Critical Implementation Gap
Despite clear guidelines, actual monitoring rates remain alarmingly low—baseline lipid testing occurs in only 8-11% of patients and glucose testing in 17-22% 5, 6. This represents a major quality gap contributing to excess cardiovascular mortality in psychiatric populations.
Bottom line: The question implies a choice between tests, but this is a false dichotomy. Both fasting glucose and lipid panels are mandatory components of antipsychotic monitoring protocols. Order both at baseline, 3 months, and annually—this is the standard of care 1.